FDA
-
-
-
-
-
-
-
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
-
-
-
-
-
-
-
Spruce Biosciences added to Russell 3000 Index
-
-
-
-
-
-
-
Spruce Biosciences presents long-term data for MPS IIIB treatment
-
-
-
-
-
-
-
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Spruce Biosciences (SPRB) Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B
-
-
-
-
-
-
-
Ladenburg Thalmann Downgrades Spruce Biosciences, Inc. (SPRB) to Neutral, 'Regulatory Path Unclear'
-
330,192 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

